{ "docId": "019dd923-622c-750b-8b99-9ee2a1e788fb", "docSlug": "1233d0b05ad9", "documentTitle": "PROCEPT BioRobotics Corporation (PRCT)", "authorId": "54_Spruce_Point_Capital", "authorName": "Spruce Point Capital Management", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-01-16 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 39, "pageCount": 100, "prevPage": 38, "nextPage": 40, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "overcrowded", "nDataPoints": 0, "notes": "Uses a combination of expert testimony and regulatory documentation to cast doubt on the safety profile of the procedure.", "elementsJson": [ "headline_text", "paragraph", "callout_box", "quote_block", "screenshot" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b99-9ee2a1e788fb/39", "deckHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb", "deckJsonHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb#slide-39", "components": [ { "bbox": { "h": 0.04, "w": 0.96, "x": 0.02, "y": 0.53 }, "kind": "callout", "text": "CMS Local Coverage Determination For Transurethral Waterjet Ablation of the Prostate", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "63047608-6d62-4854-8d67-9870de24f9e6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.96, "x": 0.02, "y": 0.27 }, "kind": "callout", "text": "Urologist Unease About Aquablation If Cancer Were Present", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f5807b57-a48c-48ab-b2ad-d51012b28f7b", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "callout", "text": "While there is no definitive link between Aquablation and the potential spread of cancer cells in the event the patient had undiagnosed prostate cancer, we found persistent fears among some urologists that the procedure could have that result.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd952-ee35-7258-b4da-4b6127fa9155", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.96, "x": 0.02, "y": 0.17 }, "kind": "paragraph", "text": "While there is no definitive link between Aquablation and the potential spread of cancer cells in the event the patient had undiagnosed prostate cancer, we found persistent fears among some urologists that the procedure could have that result. Also, current CMS guidelines still place limitations on treating patients with “known or suspected” prostate cancer.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "55407eba-b3e8-450f-8cd2-03cdcba91e86", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "I think that's a valid critique. I think although there's no data to indicate that this treatment modality could spread or lead to cancer going outside of the prostate, I think it's a valid critique because essentially you are releasing cancer cells into the urinary tract and potentially into the venous tract. So, I think in theory it makes a lot of sense. There's no data to kind of back this up, but it is a valid, I think, critique. — Private Practice Urologist", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd952-ee35-7258-b4da-4cf649302a6d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.02, "y": 0.96 }, "kind": "source-note", "text": "Source: CMS Local Coverage Determination For Transurethral Waterjet Ablation of the Prostate, Spruce Point research", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "595e2762-7f25-4ed6-afb7-56913de80470", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.18, "w": 0.96, "x": 0.02, "y": 0.32 }, "kind": "table", "text": "Spruce Point Interview with Private Practice Urologist, Dec 2024: \"I think that's a valid critique... essentially you are releasing cancer cells into the urinary tract...\"", "attrs": null, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6e1016d7-4c4c-4bf4-be1f-0f60b41ee32e", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.96, "x": 0.02, "y": 0.58 }, "kind": "table", "text": "List of limitations including: 2. Known or suspected prostate cancer (based on NCCN Prostate Cancer Early Detection guidelines) or a prostate specific antigen (PSA) >10 ng/mL unless the patient has had a negative prostate biopsy within the last 6 months.", "attrs": null, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "acb46242-caee-4d49-9ee4-facba8408f3c", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.07, "w": 0.65, "x": 0.31, "y": 0.03 }, "kind": "title", "text": "We Also Find Lingering Unease Regarding The Use Of Aquablation When Cancer May Be Present", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "942a6d1e-520f-4ecd-9997-44cccb810b6e", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "fraud-exposure", "slug": null, "matchId": "f3879d9b-e94c-4376-aa60-a6aafdb4c419", "evidence": "Uses expert testimony and regulatory text to highlight potential safety risks not fully disclosed or addressed.", "confidence": 0.9 } ], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }